CXCR1 and CXCR2 Antagonism with G31P Attenuates Chemotherapy-Induced Lung Inflammation and Augments the Gefitinib Therapeutic Response in Lung Cancer
CXCR1/2 antagonism by G31P attenuates chemotherapy-induced pulmonary inflammation and enhances the anti-tumor efficacy of gefitinib in NSCLC. These findings support the therapeutic potential of G31P as an adjuvant to epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) to improve clinical outcomes by limiting inflammation.
Authors
- Muhammad Noman Khan (ORCID: https://orcid.org/0000-0001-5509-3660)
- John Gordon (ORCID: https://orcid.org/0000-0003-3830-8070)
- Fang Li (ORCID: https://orcid.org/0000-0003-4402-2386)
- Kang Tian (ORCID: https://orcid.org/0000-0003-4766-8545)
- Song-Ze Ding
Institutions
- Hamdard University (PK)
- Dalian Medical University (CN)
- Royal University Hospital (CA)
- Henan Provincial People's Hospital (CN)
Publication Details
- Journal
- Oncology Research Featuring Preclinical and Clinical Cancer Therapeutics
- Published
- 2025-01-01
- DOI
- https://doi.org/10.32604/or.2025.069408
- Primary Topic
- Chemokine receptors and signaling
- Type
- article
- Field-Weighted Citation Impact
- 0.00